The first of a kind meeting was held in Brussels on Sep 8^th -9^th 2016 and organized by the European Organisation for Research and Treatment of Cancer (EORTC) together with the US National Cancer Institute (NCI), a governmental institution, the European Medicines Agency (EMA), a regulatory agency, and the American Association for Cancer Research (AACR). It brought together experts and stakeholders such as patient advocates, clinicians, regulators, researchers, biotech and pharmaceutical industry. The event covered a broad spectrum of topics related to the development of biomarkers in cancer research and drug development. The program and recordings of the presentations are online (http://www.eortc.org/ibcd/; http://www.informed-scientist.org/congress/innovation-and-biomarkers-in-cancer-drug-development?symfony=aead6b019915fe78536cb55a546876d1). Among other Innovative Medicines Initiative (IMI) projects, CANCER-ID has been listed by Irene Norstedt, former IMI Executive Director and Deputy Head of Unit Personalized Medicine in the EU Commission, as an example for the impact of the IMI public-private partnership on the development of personalized medicines in cancer therapy.

The meeting was preceded by the workshop “Navigating Safely Through the Regulatory Triangle” (http://www.eortc.org/regulatory/) on Sep 7^th that focused on challenges in the development and implementation of In Vitro Diagnostics (IVDs) in clinical trials. Additional information and content can be downloaded online (http://www.eortc.org/regulatory/program-2/).